AKL4 [APPA] Osteoarthritis

APPA is covered by patents granted in 37 major markets (including USA, EU, UK, Japan, Australia, NZ and India) covering composition of matter and/or medical use.

An improved formulation patent filed Q4 2017. We continue to look for ways to bolster and extend Intellectual Property.

Our lead clinical candidate is APPA, a patented, synergistic combination of two synthetic secondary metabolites of plant origin, demonstrating a low risk adverse event profile.

APPA has demonstrated repeated and significant: pain relief, function improvement and disease modification:

  • Repeated, significant pain relief and function improvement in a canine OA model; and in client owned dogs with naturally occurring OA, beyond that of the NSAID standard of care meloxicam
  • Disease modification (slowing of cartilage destruction) in the rat meniscal tear model
  • Anecdotal evidence of improved functionality and good tolerability in human named patient subjects